tag:blogger.com,1999:blog-4287560491211025099.post980186570926850638..comments2023-09-22T08:24:01.913-04:00Comments on Antibiotics - The Perfect Storm: A Path Forward for New Antibiotics. Astra Zeneca Responds.David Shlaeshttp://www.blogger.com/profile/00228776693058791618noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-4287560491211025099.post-1277777144911351002013-09-24T08:40:26.867-04:002013-09-24T08:40:26.867-04:00This is very important blog and i don't know w...This is very important blog and i don't know well about antibiotic but when i study 3 -4 blogs then i know little about antibiotic. Today, people worry that in future bacteria will not be affected by antibiotics, because bacteria might evolve and become too strong.<br />Thanks<br /><a href="http://www.pharmacy-international-direct.com/antiboitics.php" rel="nofollow">antibiotics to buy</a>Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-4287560491211025099.post-33229041794803050162013-04-01T08:31:21.604-04:002013-04-01T08:31:21.604-04:00I'm gratified that this has stimulated such a ...I'm gratified that this has stimulated such a robust discussion. My fervent hope is that the US is moving away from a pay as you go healthcare system. Medicare and the large payers seem ready to pay the high prices we discussed for antibiotics. I think it is likely therefore that the insurance exchanges under "Obamacare" would do the same here in the US. The question is - will we pay the same price for life-saving antibiotics that we now pay for meagerly life-prolonging cancer treatments?David Shlaeshttps://www.blogger.com/profile/00228776693058791618noreply@blogger.comtag:blogger.com,1999:blog-4287560491211025099.post-81030819062732721312013-03-31T17:30:20.859-04:002013-03-31T17:30:20.859-04:00I agree there are huge problems with the pipeline....I agree there are huge problems with the pipeline... However, the return on investment will not facilitate the growth of the industry and there is at least 5 if not closer to 10 years of lag. In a society (the US) where healthcare is a payer environment those whom can not afford the cost of antibiotics for currently non-resistant infections will simply forgo the treatment - this will likely harbor the infection and the spread of resistance. I appreciate that we live in a capitalistic world, but increasing the price for common treatments will not solve the problem. I have to agree with David Livermore on this... Having been an antibiotics researcher until funding forced me out of the field I also agree that we are rapidly approaching a time when thing will be irreversible.ScienceMelhttps://www.blogger.com/profile/10881828126855758298noreply@blogger.comtag:blogger.com,1999:blog-4287560491211025099.post-56762483139451770372013-03-29T08:56:47.221-04:002013-03-29T08:56:47.221-04:00Thank you for sharing your thoughts, which are sim...Thank you for sharing your thoughts, which are similar to those of many others - David Livermore in particular. But basically, we have one choice right now - provide a return on investment for pharmaceutical company shareholders or go without new antibiotics. Even if we had publicly funded antibiotic research facilities, given the costs of R&D, I'm not sure we would come out ahead. And even if we would be somewhat better off in that circumstance, we are light years away from this as a real solution. Sorry. David Shlaeshttps://www.blogger.com/profile/00228776693058791618noreply@blogger.comtag:blogger.com,1999:blog-4287560491211025099.post-86270085526557672082013-03-27T11:47:56.368-04:002013-03-27T11:47:56.368-04:00My concern from this statement - antimicrobial pri...My concern from this statement - antimicrobial prices will skyrocket given the short treatment courses. This will limit patient access, increase the spread of potentially deadly resistant infections, and ultimately not foster the R&D incentives they hope for on their investment. The real question is - when is the right thing to do more important than the capitalistic one?ScienceMelhttps://www.blogger.com/profile/10881828126855758298noreply@blogger.comtag:blogger.com,1999:blog-4287560491211025099.post-6352071168544955182013-03-26T10:56:34.876-04:002013-03-26T10:56:34.876-04:00Right. If you can interpret this in a way that in...Right. If you can interpret this in a way that indicates where Astra-ZXeneca really stands and what it means when it says that antibiotics is no longer a core area - you are a better reader than I am. What I hear is that they are skeptical about the pricing strategies for new antibiotics that have already been discussed. But what this means for their future and for their products in development - I don't know.<br />David Shlaeshttps://www.blogger.com/profile/00228776693058791618noreply@blogger.com